Business
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic
Patients Experiencing Delays to Diagnoses and Treatment, to Halting Clinical Trials, and at High Risk of Infection During Treatment MELBOURNE,
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nPatients Experiencing Delays to Diagnoses and Treatment, to Halting Clinical Trials, and at High Risk of Infection During Treatment\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that its Chief Executive Officer, Mr. James Nathanielsz, expressed concern over disruption to cancer care during the global pandemic, where patients are experiencing delays to diagnoses and treatment, to halting clinical trials. An increased risk of infection as a result of the pandemic is also a real and significant threat to the lives of cancer sufferers whilst undergoing treatment. Mr. Nathanielsz emphasized a pressing need for new and less toxic treatments must be a high priority, especially approaches that do not suppress the immune response of the patient.\n\nA recent study in Australia published in a peer reviewed journal by Edge et al, September 2021, Public Library of Science (PLOS), found that the COVID-19 pandemic has dramatically impacted cancer care worldwide. Overall, 42% of cancer patients and survivors experienced some level of disruption. Furthermore, 50% of healthcare workers agreed that patient access to research and clinical trials had been reduced.\n\nIn addition, people with cancer and their families experience greater uncertainty about their future, which may be further exacerbated by concerns about contracting the virus. For immune suppressed patients this is potentially life threatening. Sadly, infectious diseases remain a major cause of morbidity and mortality among cancer patients. Cancer can affect the immune system, increasing the risk of infection. In addition to cancer, infection can also be a primary cause of death in patients where cytotoxic chemotherapy produces severe and long-term neutropenia (too few neutrophils, an important type of white blood cell to fight infection), which may require hospitalization and lead to fatal infection. A research article published in the Biomed Central journal (BMC) by Elhadi, Khaled and Msherghi, 2021, focusing on infectious diseases as a cause of death among cancer patients in the US, concluded that timely intervention may help mitigate negative consequences on patients’ quality o...